KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Capital Expenditures (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Capital Expenditures for 13 consecutive years, with $140000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures changed N/A year-over-year to $140000.0, compared with a TTM value of $222000.0 through Sep 2025, up 107.48%, and an annual FY2023 reading of $668000.0, up 249.74% over the prior year.
  • Capital Expenditures was $140000.0 for Q3 2025 at Travere Therapeutics, up from $82000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $4.5 million in Q1 2021 and bottomed at $3000.0 in Q2 2023.
  • Average Capital Expenditures over 5 years is $441571.4, with a median of $92500.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures tumbled 97.09% in 2022, then skyrocketed 2633.33% in 2024.
  • Year by year, Capital Expenditures stood at $154000.0 in 2021, then tumbled by 80.52% to $30000.0 in 2022, then decreased by 16.67% to $25000.0 in 2023, then skyrocketed by 228.0% to $82000.0 in 2024, then surged by 70.73% to $140000.0 in 2025.
  • Business Quant data shows Capital Expenditures for TVTX at $140000.0 in Q3 2025, $82000.0 in Q2 2024, and $25000.0 in Q4 2023.